BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33381579)

  • 1. Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data.
    Hassan WM; Bakry MS; Siepmann T; Illigens B
    Biomed Res Int; 2020; 2020():7390473. PubMed ID: 33381579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors.
    Michalowski MB; de Fraipont F; Plantaz D; Michelland S; Combaret V; Favrot MC
    Pediatr Blood Cancer; 2008 Jan; 50(1):29-32. PubMed ID: 17570703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
    Haruta M; Kamijo T; Nakagawara A; Kaneko Y
    Cancer Lett; 2014 Jun; 348(1-2):167-76. PubMed ID: 24680815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.
    Yang Q; Kiernan CM; Tian Y; Salwen HR; Chlenski A; Brumback BA; London WB; Cohn SL
    Clin Cancer Res; 2007 Jun; 13(11):3191-7. PubMed ID: 17545522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbon dioxide does not affect the methylation status of prognostic important oncogenes Rassf1A and DCR2 in neuroblastoma cells.
    Reismann M; Lehmann D; Quandte M; Ure BM; Glüer S
    Pediatr Surg Int; 2008 Dec; 24(12):1327-30. PubMed ID: 19002696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors.
    Banelli B; Gelvi I; Di Vinci A; Scaruffi P; Casciano I; Allemanni G; Bonassi S; Tonini GP; Romani M
    Oncogene; 2005 Aug; 24(36):5619-28. PubMed ID: 16044164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
    van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
    Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clustering of hypermethylated genes in neuroblastoma.
    van Noesel MM; van Bezouw S; Voûte PA; Herman JG; Pieters R; Versteeg R
    Genes Chromosomes Cancer; 2003 Nov; 38(3):226-33. PubMed ID: 14506696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.
    Kiss NB; Kogner P; Johnsen JI; Martinsson T; Larsson C; Geli J
    BMC Med Genet; 2012 Sep; 13():83. PubMed ID: 22984959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
    Hoebeeck J; Michels E; Pattyn F; Combaret V; Vermeulen J; Yigit N; Hoyoux C; Laureys G; De Paepe A; Speleman F; Vandesompele J
    Cancer Lett; 2009 Jan; 273(2):336-46. PubMed ID: 18819746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
    Decock A; Ongenaert M; Vandesompele J; Speleman F
    Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas.
    Margetts CD; Astuti D; Gentle DC; Cooper WN; Cascon A; Catchpoole D; Robledo M; Neumann HP; Latif F; Maher ER
    Endocr Relat Cancer; 2005 Mar; 12(1):161-72. PubMed ID: 15788647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-8 gene expression in neuroblastoma.
    Casciano I; Banelli B; Croce M; De Ambrosis A; di Vinci A; Gelvi I; Pagnan G; Brignole C; Allemanni G; Ferrini S; Ponzoni M; Romani M
    Ann N Y Acad Sci; 2004 Dec; 1028():157-67. PubMed ID: 15650242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.